ADMA Biologics (ADMA) PT Raised to $18 at Maxim Group

Maxim Group analyst Jason Kolbert reiterated a Buy rating and boosted his price target on ADMA Biologics (NASDAQ: ADMA) to $18.00 (from $16.00) as they roll their valuation metrics forward to 2015.

Kolbert highlighted:

• We recently spent time with management, and our confidence level in the company executing its business plan is high. For example, ADMA uplisted to the Nasdaq (as promised) and opened a second collection facility.
• We are expecting a data readout from the RI-002 (IVIG) phase III study by YE2014 to be followed by a BLA filing early in 2015 and projected launch in 2016.
• With $20M in cash (at end of 3Q14), ADMA is funded through its phase III pivotal trial for RI-002 IVIG.
• The company presented RI-002 data at the RSV symposium in South Africa last month.

For an analyst ratings summary and ratings history on ADMA Biologics click here. For more ratings news on ADMA Biologics click here.

Shares of ADMA Biologics closed at $12.37 yesterday.

You May Also Be Interested In

• Artivion Inc. (AORT) PT Raised to $40 at Canaccord
• BNP Paribas Exane Downgrades Lanxess AG (LXS:GR) (LNXSF) to Underperform
• Axis Capital Limited Upgrades Colgate-Palmolive India (CLGT:IN) to Add (2)